健康元：健康元药业集团股份有限公司2025年年度报告（英文版）

1 Important Notice I. The Board ofDirectors (the “Board”),directorsand senior management ofthe Companyhereby warrant the truthfulness, accuracy and completeness of the contents of this annualreport (the “Report”), and that there are no false representations, misleading statements ormaterial omissions contained in the Report,and severally and jointly accept legalresponsibility. II. All directors ofthe Companyattended the Board meeting. III. Grant Thornton issued a standard unqualified audit report forthe Company. IV. Mr. ZhuBaoguo (朱保国), the person-in-charge ofthe Company, and Mr. Qiu Qingfeng(邱庆丰), the person-in-charge of accounting work,andMs. Guo Chenlu (郭琛璐),the person-in-charge of the accounting department (the head of the accounting department) declare thatthey hereby warrant the truthfulness, accuracy and completeness of the financial statementscontained in the Report. V. Profit distribution plan or plan for conversion of capital reserve to share capital approvedby the Board resolution during theReportingPeriod Based on the audit conducted by Grant Thornton, as of 31 December 2025,the undistributed profitin the parent company statement ofthe Companyamounted to RMB2,775.7845million.Pursuanttothe resolution ofthe Company's Board of Directors,the Companyplans to distribute cashdividends for the fiscal year 2025,based onthe Company’s total share capital on the record date tobe determined upon implementation of the 2025 profit distribution plan.The Companyplans todistributeacash dividend ofRMB2.20(tax inclusive) for every 10 shares to all shareholders oftheCompany, and the remaining undistributed profits will be carried forward to the following year. As of the end of theReporting Period, details regarding theaccumulated losses not yetoffsetof the parent company and their impact on matters such as dividend distribution.□Applicable √N/A VI.Riskwarning forforward-lookingstatements √Applicable □N/AThe Report contains forward-looking statements which involve the future plans, developmentstrategies, etc. ofthe Company, yet do not constitute substantive undertakings ofthe Companytoinvestors. Investors should exercise caution prior to making investment decisions. VII. Whether there is non-operating use of funds by the controlling shareholder and theirrelated partiesNo VIII. Whether there is a violation of the prescribed decision-making procedures to provideexternal guaranteesNo IX. Whether more than half of directors cannot warrant the truthfulness, accuracy andcompleteness of the Report disclosed bythe CompanyNo X. Significant risk warnings There were no material risks that had a substantial impacton the production and operation oftheCompanyduring theReporting Period. In this Report,the Companyhas elaborated on the risks andcountermeasures thatthe Companymay face in the course of production and operation, includingindustry policy risk, market risk, risk of safety and environmental protection,raw material pricevolatility and supply risksand R&D risk. For more information, please refer to “PotentialRisks”part in Chapter 3 Management Discussion and Analysis. XI. Others□Applicable √N/A Table of Contents Important Notice.............................................................................................................................1Financial Highlights........................................................................................................................7Chapter1 Definitions......................................................................................................................8Chapter 2 Company Profile and Major Financial Indicators...................................................10Chapter 3 Management Discussion and Analysis......................................................................15Chapter 4 Corporate Governance,Environment and Social....................................................71Chapter 5Major Events...............................................................................................................94Chapter 6 Changes in Equity and Shareholders......................................................................115Chapter 7 Information on Bonds...............................................................................................122Chapter 8 Financial Statements.................................................................................................123 Moving with the Times, Embracing the New —A Letter to All Shareholders DearShareholders, As we look back on 2025, we find ourselves standing together at a historicturning point. The global pharmaceutical industry is undergoing a transformation of unprecedented scale—wavesof innovation surge relentlessly forward, artificial intelligence accelerates its evolution, and globalexpansion continues to deepen. Multipleforces of change converge and intertwine, and a definingwatershed moment for our era has arrived. In the face of this powerful tide of history, Join